Paul O'Brien

Paul O’Brien, Ph.D., is a Senior Research Associate at Patient Square Capital, where he is part of the Patient Square Insights team. In this capacity, he conducts in-depth research and analysis focused on healthcare investment opportunities, especially those in therapeutics and biopharmaceuticals. His work supports firmwide strategy and due diligence efforts within the healthcare sector.

Dr. O'Brien's career spans both investment and operational roles in healthcare, including his recent tenure as Associate Director of M&A at BridgeBio Pharma, where he evaluated clinical and commercial-stage healthcare companies in the therapeutics segment. He previously held positions at Point72 and Regeneron Pharmaceuticals, bringing a broad perspective across investment management and industry research. His sector coverage includes therapeutics, life sciences, and healthcare technologies.

Holding a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University, along with a Master’s and Bachelor’s degrees in Biotechnology and Chemical/Biomolecular Engineering from the University of Pennsylvania, Dr. O’Brien leverages deep scientific expertise in his investment work. He is recognized for his rigorous approach to healthcare opportunity assessment and contributions to cross-disciplinary investment insights in the biopharma domain.